Andreas Dam: Transforming how pharma engages with patients and HCPs
Send us Fan Mail
Are pharmaceutical companies allowed to engage with patients and HCPs? Judging by how infrequent such interactions are, you might get the sense that it is strictly forbidden. Though such interactions are regulated, navigating these for the promise of understanding the perspective of the clinicians as well as patients is worthwhile.
We speak to Andreas Dam, the founder and CEO of Daman, about patient empowerment in clinical trials and how pharma can come closer to patients and HCPs.
Life sciences are impacted by two major trends: the larger consumerization trend and the shift…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.